Pliant Therapeutics (PLRX) Competitors $1.25 +0.05 (+3.75%) Closing price 07/3/2025 03:40 PM EasternExtended Trading$1.25 0.00 (0.00%) As of 07/3/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PLRX vs. LFCR, BNTC, AVIR, IVA, AARD, OCGN, GOSS, ALT, GLUE, and RNACShould you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Lifecore Biomedical (LFCR), Benitec Biopharma (BNTC), Atea Pharmaceuticals (AVIR), Inventiva (IVA), Aardvark Therapeutics (AARD), Ocugen (OCGN), Gossamer Bio (GOSS), Altimmune (ALT), Monte Rosa Therapeutics (GLUE), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical products" industry. Pliant Therapeutics vs. Its Competitors Lifecore Biomedical Benitec Biopharma Atea Pharmaceuticals Inventiva Aardvark Therapeutics Ocugen Gossamer Bio Altimmune Monte Rosa Therapeutics Cartesian Therapeutics Lifecore Biomedical (NASDAQ:LFCR) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation. Which has preferable earnings & valuation, LFCR or PLRX? Lifecore Biomedical has higher revenue and earnings than Pliant Therapeutics. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifecore Biomedical$128.26M2.32$12.01M-$1.45-5.54Pliant Therapeutics$1.58M48.37-$210.30M-$3.61-0.34 Does the media prefer LFCR or PLRX? In the previous week, Lifecore Biomedical's average media sentiment score of 0.00 equaled Pliant Therapeutics'average media sentiment score. Company Overall Sentiment Lifecore Biomedical Neutral Pliant Therapeutics Neutral Which has more volatility and risk, LFCR or PLRX? Lifecore Biomedical has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Is LFCR or PLRX more profitable? Pliant Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -35.90%. Pliant Therapeutics' return on equity of -67.56% beat Lifecore Biomedical's return on equity.Company Net Margins Return on Equity Return on Assets Lifecore Biomedical-35.90% -551.09% -13.89% Pliant Therapeutics N/A -67.56%-52.54% Do insiders & institutionals hold more shares of LFCR or PLRX? 83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 32.2% of Lifecore Biomedical shares are owned by insiders. Comparatively, 8.0% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate LFCR or PLRX? Lifecore Biomedical presently has a consensus price target of $8.00, suggesting a potential downside of 0.37%. Pliant Therapeutics has a consensus price target of $13.31, suggesting a potential upside of 969.28%. Given Pliant Therapeutics' higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than Lifecore Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifecore Biomedical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Pliant Therapeutics 0 Sell rating(s) 12 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryLifecore Biomedical and Pliant Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRX vs. The Competition Export to ExcelMetricPliant TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.35M$2.91B$5.56B$9.03BDividend YieldN/A2.44%5.22%3.99%P/E Ratio-0.3421.5627.6920.25Price / Sales48.37246.41389.63163.10Price / CashN/A42.7336.8958.10Price / Book0.257.518.035.67Net Income-$210.30M-$55.14M$3.18B$249.21M7 Day Performance-0.40%4.61%2.93%3.28%1 Month Performance-23.62%0.90%1.72%3.95%1 Year Performance-88.17%5.40%34.39%20.98% Pliant Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRXPliant Therapeutics3.9903 of 5 stars$1.25+3.8%$13.31+969.3%-88.2%$77.35M$1.58M-0.3490LFCRLifecore Biomedical1.0127 of 5 stars$8.12-0.9%$8.00-1.5%+64.2%$303.24M$128.26M0.00690High Trading VolumeBNTCBenitec Biopharma2.0181 of 5 stars$11.70+3.1%$23.83+103.7%+41.4%$297.94M$80K0.0020High Trading VolumeAVIRAtea Pharmaceuticals2.3525 of 5 stars$3.60+4.3%$6.00+66.7%+12.9%$295.25MN/A0.0070High Trading VolumeIVAInventiva2.7676 of 5 stars$3.19+4.6%$10.40+226.0%+3.7%$291.77M$9.95M0.00100News CoverageGap UpAARDAardvark TherapeuticsN/A$13.52+1.0%$33.00+144.1%N/A$290.51MN/A0.0018News CoverageAnalyst RevisionGap UpOCGNOcugen0.9768 of 5 stars$0.97-1.4%$6.00+518.3%-43.5%$287.39M$4.05M0.0080High Trading VolumeGOSSGossamer Bio3.6632 of 5 stars$1.23-1.6%$7.33+496.2%+13.4%$284.13M$114.70M0.00180ALTAltimmune2.2271 of 5 stars$3.87+10.6%$19.00+391.0%-28.1%$283.87M$20K0.0050High Trading VolumeGLUEMonte Rosa Therapeutics1.3498 of 5 stars$4.51-2.0%$15.33+240.0%+38.6%$282.95M$75.62M57.5090News CoverageRNACCartesian Therapeutics1.4327 of 5 stars$10.39-2.7%$41.25+297.0%-34.1%$277.19M$38.91M0.0064 Related Companies and Tools Related Companies LFCR Alternatives BNTC Alternatives AVIR Alternatives IVA Alternatives AARD Alternatives OCGN Alternatives GOSS Alternatives ALT Alternatives GLUE Alternatives RNAC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRX) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
